| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1025958291 |
| P356 | DOI | 10.1038/NRI2315 |
| P698 | PubMed publication ID | 18437156 |
| P5875 | ResearchGate publication ID | 5416061 |
| P50 | author | Simon Fillatreau | Q37340659 |
| P2093 | author name string | David Gray | |
| Stephen M Anderton | |||
| P2860 | cites work | Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden | Q22255575 |
| Interleukin-10 and the interleukin-10 receptor | Q24290912 | ||
| ICOS co-stimulatory receptor is essential for T-cell activation and function | Q28187985 | ||
| B-cell depletion with rituximab in relapsing-remitting multiple sclerosis | Q28268626 | ||
| Association between parasite infection and immune responses in multiple sclerosis | Q28283893 | ||
| Germinal centers | Q29616234 | ||
| The effect of infections on susceptibility to autoimmune and allergic diseases | Q29618525 | ||
| B7h, a novel costimulatory homolog of B7.1 and B7.2, is induced by TNFalpha | Q30807749 | ||
| Mesenteric B cells centrally inhibit CD4+ T cell colitis through interaction with regulatory T cell subsets | Q33836834 | ||
| B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. | Q33869680 | ||
| B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms | Q34067347 | ||
| Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice | Q34083166 | ||
| B cells regulate autoimmunity by provision of IL-10. | Q34150590 | ||
| Prevention of arthritis by interleukin 10-producing B cells | Q34178104 | ||
| Innate immunity mediated by TLR9 modulates pathogenicity in an animal model of multiple sclerosis | Q34312767 | ||
| Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice | Q34411828 | ||
| CpG motifs in bacterial DNA and their immune effects | Q34542287 | ||
| Novel suppressive function of transitional 2 B cells in experimental arthritis | Q34634297 | ||
| Oligosaccharide-specific induction of interleukin 10 production by B220+ cells from schistosome-infected mice: a mechanism for regulation of CD4+ T-cell subsets | Q34877563 | ||
| A role for inflammatory mediators in the induction of immunoregulatory B cells | Q35053422 | ||
| Inhibitory role of CD19 in the progression of experimental autoimmune encephalomyelitis by regulating cytokine response | Q35087990 | ||
| Differential signaling by CpG DNA in DCs and B cells: not just TLR9 | Q35557262 | ||
| Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics | Q35787456 | ||
| Apoptotic cells protect mice from autoimmune inflammation by the induction of regulatory B cells | Q35956837 | ||
| Inflammatory arthritis can be reined in by CpG-induced DC-NK cell cross talk. | Q36229564 | ||
| Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats | Q36230998 | ||
| B cell depletion in autoimmune rheumatic diseases | Q36246871 | ||
| Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells | Q36365297 | ||
| B lymphocytes regulate dendritic cell (DC) function in vivo: increased interleukin 12 production by DCs from B cell-deficient mice results in T helper cell type 1 deviation | Q36368717 | ||
| CD4+CD25+ T regulatory cells dependent on ICOS promote regulation of effector cells in the prediabetic lesion | Q36399063 | ||
| An interleukin (IL)-10/IL-12 immunoregulatory circuit controls susceptibility to autoimmune disease. | Q36400329 | ||
| Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes. | Q36401271 | ||
| B cell immunobiology in disease: evolving concepts from the clinic | Q36427357 | ||
| Epidemiological study of multiple sclerosis in Israel. II. Multiple sclerosis and level of sanitation | Q37123802 | ||
| TLR-mediated stimulation of APC: Distinct cytokine responses of B cells and dendritic cells. | Q37235039 | ||
| Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production | Q37354525 | ||
| Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling | Q38319700 | ||
| Upon TLR9 signaling, CD5+ B cells control the IL-12-dependent Th1-priming capacity of neonatal DCs. | Q38327677 | ||
| B-cell outgrowth and ligand-specific production of IL-10 correlate with Th2 dominance in certain parasitic diseases | Q39334507 | ||
| IL-10 production in B cells is confined to CD154+ cells in patients with systemic lupus erythematosus | Q42471179 | ||
| Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand | Q42767299 | ||
| Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice | Q42942093 | ||
| The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor alpha mutant mice | Q43640297 | ||
| A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells | Q43756252 | ||
| Assessment of Be1 and Be2 cells in systemic lupus erythematosus indicates elevated interleukin-10 producing CD5+ B cells. | Q44452630 | ||
| B cell developmental requirement for the G alpha i2 gene | Q44785598 | ||
| Polyoma virus-like particles elicit polarized cytokine responses in APCs from tumor-susceptible and -resistant mice | Q45246234 | ||
| TLR-activated B cells suppress T cell-mediated autoimmunity | Q46434575 | ||
| Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO. | Q46831933 | ||
| Levels of autoantibodies, unlike antibodies to all extrinsic antigen groups, fall following B cell depletion with Rituximab | Q46846243 | ||
| Maturation of dendritic cell 2 phenotype by a helminth glycan uses a Toll-like receptor 4-dependent mechanism | Q47368677 | ||
| An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells | Q47839224 | ||
| Distinct profiles of human B cell effector cytokines: a role in immune regulation? | Q47992004 | ||
| The costimulatory molecule ICOS plays an important role in the immunopathogenesis of EAE. | Q48827709 | ||
| Ulcerative colitis and adenocarcinoma of the colon in G alpha i2-deficient mice. | Q53463453 | ||
| Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. | Q53555780 | ||
| Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system. | Q53846430 | ||
| Helminth infection protects mice from anaphylaxis via IL-10-producing B cells. | Q53880583 | ||
| Production of cytokines by mouse B cells: B lymphomas and normal B cells produce interleukin 10 | Q56987761 | ||
| Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells | Q61027392 | ||
| Phenotype of B cells responding to the thymus-independent type-2 antigen polyvinyl pyrrolidinone | Q71163003 | ||
| Modulation of the IL-10/IL-12 cytokine circuit by interferon-beta inhibits the development of epitope spreading and disease progression in murine autoimmune encephalomyelitis | Q73153718 | ||
| Reciprocal regulation of polarized cytokine production by effector B and T cells | Q73256871 | ||
| Subversion of the innate immune system by a retrovirus | Q73350976 | ||
| IL-10 and the dangers of immune polarization: excessive type 1 and type 2 cytokine responses induce distinct forms of lethal immunopathology in murine schistosomiasis | Q73869153 | ||
| Clinical and biologic effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus | Q74175872 | ||
| IL-10 regulates murine lupus | Q74583324 | ||
| Cutting Edge: Ectopic expression of CD40 ligand on B cells induces lupus-like autoimmune disease | Q77373855 | ||
| Chronic intestinal inflammatory condition generates IL-10-producing regulatory B cell subset characterized by CD1d upregulation | Q77704355 | ||
| Requirement for phosphoinositide 3-kinase p110delta signaling in B cell antigen receptor-mediated antigen presentation | Q79718013 | ||
| B cell regulation of CD4+CD25+ T regulatory cells and IL-10 via B7 is essential for recovery from experimental autoimmune encephalomyelitis | Q79880391 | ||
| Invariant V(alpha)19i T cells regulate autoimmune inflammation | Q80027644 | ||
| Association of interleukin-10 promoter polymorphisms with systemic lupus erythematosus | Q80419608 | ||
| The inflamed central nervous system drives the activation and rapid proliferation of Foxp3+ regulatory T cells | Q80582218 | ||
| B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity | Q81452723 | ||
| Regulation of IFN-gamma production by B effector 1 cells: essential roles for T-bet and the IFN-gamma receptor | Q81767199 | ||
| Peripheral tolerance via the anterior chamber of the eye: role of B cells in MHC class I and II antigen presentation | Q83276350 | ||
| Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice | Q95789881 | ||
| P433 | issue | 5 | |
| P921 | main subject | pathology | Q7208 |
| P304 | page(s) | 391-397 | |
| P577 | publication date | 2008-05-01 | |
| P1433 | published in | Nature Reviews Immunology | Q43355 |
| P1476 | title | Not always the bad guys: B cells as regulators of autoimmune pathology | |
| P478 | volume | 8 |
| Q33403761 | A New Kid on the Block: IL-10+ Regulatory B Cells and a Possible Role In Psoriasis |
| Q37577571 | A perspective on B-cell-targeting therapy for SLE. |
| Q37335863 | Activated B cells in autoimmune diseases: the case for a regulatory role |
| Q35097618 | Activated peritoneal cavity B-1a cells possess regulatory B cell properties |
| Q37593519 | Activation of human B cells negatively regulates TGF-β1 production |
| Q38097385 | Adaptive immune responses in CNS autoimmune disease: mechanisms and therapeutic opportunities |
| Q37413671 | Altered Interleukin-10 Signaling in Skeletal Muscle Regulates Obesity-Mediated Inflammation and Insulin Resistance |
| Q37045312 | Amelioration of autoimmune arthritis by adoptive transfer of Foxp3-expressing regulatory B cells is associated with the Treg/Th17 cell balance |
| Q31027910 | Amplified B lymphocyte CD40 signaling drives regulatory B10 cell expansion in mice |
| Q37791260 | Animal models of IBD: linkage to human disease |
| Q38525103 | Antibody-independent functions of B cells: a focus on cytokines |
| Q84149041 | Association of promoter region single nucleotide polymorphisms at positions -819C/T and -592C/A of interleukin 10 gene with ischemic heart disease |
| Q50856763 | Autocrine IL-10 promotes human B-cell differentiation into IgM- or IgG-secreting plasmablasts. |
| Q38065286 | Autophagy and intestinal homeostasis |
| Q36954468 | B Cell in Autoimmune Diseases |
| Q37093281 | B Lymphocytes in Multiple Sclerosis: Bregs and BTLA/CD272 Expressing-CD19+ Lymphocytes Modulate Disease Severity |
| Q38095860 | B cell biology: implications for treatment of systemic lupus erythematosus |
| Q35946128 | B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells |
| Q34678839 | B cell depletion therapy exacerbates murine primary biliary cirrhosis |
| Q37314912 | B cell-derived transforming growth factor-β1 expression limits the induction phase of autoimmune neuroinflammation. |
| Q37039335 | B cells as effectors and regulators of sex-biased arthritis. |
| Q38649554 | B cells as multi-functional players during Mycobacterium tuberculosis infection and disease. |
| Q37603296 | B cells as therapeutic targets in SLE. |
| Q37994807 | B cells in allergic diseases: bad or better? |
| Q84767437 | B cells in autoimmunity |
| Q33684762 | B cells inhibit the antitumor immunity against an established murine fibrosarcoma |
| Q50763118 | B cells produce less IL-10, IL-6 and TNF-α in myasthenia gravis. |
| Q44699204 | B-cell biology and related therapies in systemic lupus erythematosus |
| Q37155196 | B-cell diversity decreases in old age and is correlated with poor health status |
| Q81329072 | B-cell-derived interleukin-10 in autoimmune disease: regulating the regulators |
| Q37815038 | B-lymphocyte effector functions in health and disease |
| Q27318165 | CD19(+) B cells confer protection against experimental cerebral malaria in semi-immune rodent model |
| Q37173667 | CD22 expression mediates the regulatory functions of peritoneal B-1a cells during the remission phase of contact hypersensitivity reactions |
| Q26772339 | CD8(+) T-Cells as Immune Regulators of Multiple Sclerosis |
| Q53229165 | Characterisation of Tertiary Lymphoid Organs in Explanted Rejected Donor Kidneys. |
| Q34144779 | Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. |
| Q39570916 | Characterization of responses elicited by Toll-like receptor agonists in cells of the bursa of Fabricius in chickens |
| Q33631398 | Chronic helminth infections protect against allergic diseases by active regulatory processes |
| Q38988547 | Cinnamon and Chronic Diseases. |
| Q34670989 | Cinnamon extract suppresses experimental colitis through modulation of antigen-presenting cells |
| Q46959933 | Co-activation through TLR4 and TLR9 but not TLR2 skews Treg-mediated modulation of Igs and induces IL-17 secretion in Treg: B cell co-cultures |
| Q33765164 | CpG-enhanced CD8+ T-cell responses to peptide immunization are severely inhibited by B cells |
| Q33816764 | Critical role for thymic CD19+CD5+CD1dhiIL-10+ regulatory B cells in immune homeostasis |
| Q34132601 | Crohn disease: a current perspective on genetics, autophagy and immunity |
| Q35606563 | Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis |
| Q36905571 | Cutting Edge: Integrin α4 Is Required for Regulatory B Cell Control of Experimental Autoimmune Encephalomyelitis |
| Q37886819 | Cytokine networks in glioma |
| Q37349889 | Cytokine-producing effector B cells regulate type 2 immunity to H. polygyrus. |
| Q37867728 | Development of anti-CD20 therapy for multiple sclerosis. |
| Q34790761 | Differential effects of Radix Paeoniae Rubra (Chishao) on cytokine and chemokine expression inducible by mycobacteria |
| Q37708012 | Effector and regulatory B cells: modulators of CD4+ T cell immunity |
| Q37997855 | Effector and regulatory roles for B cells in HIV infection? |
| Q41268957 | Fingolimod treatment promotes regulatory phenotype and function of B cells |
| Q27315104 | Fish and mammalian phagocytes differentially regulate pro-inflammatory and homeostatic responses in vivo |
| Q35562921 | General Approach for Tetramer-Based Identification of Autoantigen-Reactive B Cells: Characterization of La- and snRNP-Reactive B Cells in Autoimmune BXD2 Mice |
| Q37453992 | Genetics of rheumatic disease |
| Q35230822 | Helminth-induced CD19+CD23hi B cells modulate experimental allergic and autoimmune inflammation |
| Q36567307 | Helminths: Immunoregulation and Inflammatory Diseases-Which Side Are Trichinella spp. and Toxocara spp. on? |
| Q28387176 | High basal activity of the PTPN22 gain-of-function variant blunts leukocyte responsiveness negatively affecting IL-10 production in ANCA vasculitis |
| Q37637477 | IL-10-Producing CD1dhiCD5+ Regulatory B Cells May Play a Critical Role in Modulating Immune Homeostasis in Silicosis Patients |
| Q38497062 | IL-10-independent regulatory B-cell subsets and mechanisms of action |
| Q38101674 | IL-10-producing lymphocytes in inflammatory disease |
| Q36760499 | IL-10-producing regulatory B cells (B10 cells) in autoimmune disease |
| Q34658996 | IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases |
| Q51038853 | IL‐10 produced by activated human B cells regulates CD4+ T‐cell activation in vitro |
| Q33882845 | Identification of a B cell signature associated with renal transplant tolerance in humans. |
| Q39021026 | Induction and Differentiation of IL-10-Producing Regulatory B Cells from Healthy Blood Donors and Rheumatoid Arthritis Patients. |
| Q37883443 | Inflamed gut mucosa: downstream of interleukin-10. |
| Q47161833 | Inflammatory Conditions Dictate the Effect of Mesenchymal Stem or Stromal Cells on B Cell Function |
| Q37436035 | Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targets |
| Q35858342 | Interleukin-10 promoter polymorphism and susceptibility to lung cancer: a systematic review and meta-analysis |
| Q34486748 | Interleukin-10: an anti-inflammatory marker to target atherosclerotic lesions via PEGylated liposomes. |
| Q24653771 | Interleukin-10: new perspectives on an old cytokine |
| Q33721777 | Interleukin-35 induces regulatory B cells that suppress autoimmune disease. |
| Q33943014 | Killer B lymphocytes: the evidence and the potential |
| Q34645411 | Limited sufficiency of antigen presentation by dendritic cells in models of central nervous system autoimmunity. |
| Q35896923 | Lipopolysaccharide Attenuates CD40 Ligand-Induced Regulatory B10 Cell Expansion and IL-10 Production in Mouse Splenocytes |
| Q39084586 | Lymphoid Neogenesis and Tertiary Lymphoid Organs in Transplanted Organs. |
| Q86557423 | MS risk allele rs1883832T is associated with decreased mRNA expression of CD40 |
| Q33740580 | Mechanisms of Autoantibody-Induced Pathology. |
| Q59271653 | Mechanisms of allergen-specific immunotherapy |
| Q42016073 | Micro RNA-17-92 cluster mediates interleukin-4-suppressed IL-10 expression in B cells |
| Q37814815 | Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges |
| Q39545578 | Most B cells in non-lymphoid tissues are naïve. |
| Q36190929 | Mucosal immunoglobulins and B cells of teleost fish |
| Q27011014 | Multiple sclerosis: the role of cytokines in pathogenesis and in therapies |
| Q41616016 | NMDA-receptor antagonists block B-cell function but foster IL-10 production in BCR/CD40-activated B cells |
| Q38062945 | Natural autoantibodies and associated B cells in immunity and autoimmunity |
| Q36011177 | New insights into B cell biology in systemic lupus erythematosus and Sjögren's syndrome |
| Q27025655 | Novel developments in the mechanisms of immune tolerance to allergens |
| Q37846865 | Novel regulatory functions for Toll-like receptor-activated B cells during intracellular bacterial infection |
| Q51051161 | Patients with drug-free long-term graft function display increased numbers of peripheral B cells with a memory and inhibitory phenotype. |
| Q34193317 | Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. |
| Q44761134 | Presentation of the candidate rheumatoid arthritis autoantigen aggrecan by antigen-specific B cells induces enhanced CD4(+) T helper type 1 subset differentiation |
| Q34063315 | Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus |
| Q30278502 | Rapamycin prevents bronchiolitis obliterans through increasing infiltration of regulatory B cells in a murine tracheal transplantation model |
| Q33829700 | Rationale for B cell targeting in SLE |
| Q38071110 | Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity |
| Q37350948 | Reduced Fas ligand-expressing splenic CD5+ B lymphocytes in severe collagen-induced arthritis. |
| Q41980478 | Regulatory B Cells in Seropositive Myasthenia Gravis versus Healthy Controls. |
| Q35484992 | Regulatory B cell production of IL-10 inhibits lymphoma depletion during CD20 immunotherapy in mice. |
| Q37072801 | Regulatory B cells (B10 cells) have a suppressive role in murine lupus: CD19 and B10 cell deficiency exacerbates systemic autoimmunity |
| Q35062229 | Regulatory B cells and allergic diseases |
| Q82387544 | Regulatory B cells and their role in maintaining peripheral tolerance |
| Q37095181 | Regulatory B cells in autoimmune diseases and mucosal immune homeostasis |
| Q64911683 | Regulatory B cells in myasthenia gravis are differentially affected by therapies. |
| Q92001638 | Regulatory and Memory B Lymphocytes in Children With Newly Diagnosed Immune Thrombocytopenia |
| Q38013048 | Regulatory immune cells in transplantation |
| Q41684352 | Renal transplant recipient with advanced HIV infection: graft and peripheral cell population analysis |
| Q34495557 | Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. |
| Q41771883 | Role of B cells in systemic lupus erythematosus and rheumatoid arthritis |
| Q36529131 | Role of autoimmunity in primary biliary cirrhosis |
| Q38384621 | Role of the innate and adaptive immune responses in the course of multiple sclerosis |
| Q55347406 | Sialylated Autoantigen-Reactive IgG Antibodies Attenuate Disease Development in Autoimmune Mouse Models of Lupus Nephritis and Rheumatoid Arthritis. |
| Q38468652 | Signals controlling the development and activity of regulatory B-lineage cells |
| Q44124678 | Significance of B10 cell in patients with thymoma complicated with myasthenia gravis |
| Q42557987 | TLR and B cell receptor signals to B cells differentially program primary and memory Th1 responses to Salmonella enterica |
| Q42557989 | TLR-mediated loss of CD62L focuses B cell traffic to the spleen during Salmonella typhimurium infection |
| Q42017364 | TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors |
| Q38008349 | TLRs, Treg, and B Cells, an Interplay of Regulation during Helminth Infection |
| Q55234556 | Targeting B Cells and Plasma Cells in Autoimmune Diseases. |
| Q38207937 | Targeting B cells and autoantibodies in the therapy of autoimmune diseases |
| Q38196752 | Targeting IL-10 in auto-immune diseases |
| Q58148731 | The B-side story in insulin resistance |
| Q34673861 | The biology of intestinal immunoglobulin A responses |
| Q37069155 | The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals |
| Q36737978 | The interleukin 10 -819C/T polymorphism and cancer risk: a HuGE review and meta-analysis of 73 studies including 15,942 cases and 22,336 controls |
| Q57667575 | The multiple sclerosis whole blood mRNA transcriptome and genetic associations indicate dysregulation of specific T cell pathways in pathogenesis |
| Q38203097 | The role of B regulatory cells and Semaphorin3A in atopic diseases |
| Q34792884 | To B or not to B: B cells and the Th2-type immune response to helminths |
| Q50249568 | Transparent Substrates Prepared From Different Amorphous Polymers Can Directly Modulate Primary Human B cell functions |
| Q38150110 | Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys |
| Q36504624 | Treatment targets in systemic lupus erythematosus: biology and clinical perspective |
| Q35424431 | Uptake and presentation of myelin basic protein by normal human B cells |
| Q34610624 | Vaccination strategies to promote mucosal antibody responses. |
| Q37420512 | Vitamin B(12) and folic acid imbalance modifies NK cytotoxicity, lymphocytes B and lymphoprolipheration in aged rats |
| Q82249253 | What are regulatory B cells? |
| Q40273988 | What do we know about the role of regulatory B cells (Breg) during the course of infection of two major parasitic diseases, malaria and leishmaniasis? |
| Q84036435 | [Translational aspects on the role of B-cells in autoimmune diseases. "From bench to bedside" and "from bed to benchside"] |
Search more.